Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr-Jun;13(2):209-214.
doi: 10.4183/aeb.2017.209.

PREDICTIVE CIRCULATING MARKERS FOR ANTHRACYCLINE CHEMOTHERAPY IN NON-METASTATIC BREAST CANCER

I Botnariuc  1 , S M Ilie  1 , O G Trifanescu  1 , X E Bacinschi  1 , F Curea  1 , R M Anghel  1
Affiliations
Review

PREDICTIVE CIRCULATING MARKERS FOR ANTHRACYCLINE CHEMOTHERAPY IN NON-METASTATIC BREAST CANCER

I Botnariuc et al. Acta Endocrinol (Buchar). 2017 Apr-Jun.

Abstract

Anthracyclines are used in breast cancer both in early and advanced stages and their recommendation together with taxanes, either concurrently or sequentially, is debatable and individualized by phenotype. Circulating biomarkers have already been introduced in clinical practice for metastatic disease monitoring. We questioned whether it might be a role for these markers in neoadjuvant and adjuvant settings too and a general review was conducted. CK18 and CTC were found predictive for anthracycline related response in preoperative setting. Soluble E-cadherin is promising, a retrospective analysis showing a direct correlation with clinical response. CEA, CA 15-3 and HER2 ECD are not of interest for their predictive role.

Keywords: anthracyclines; breast cancer; circulating biomarkers.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest concerning this article.

References

    1. Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 2005;93(9):1046–1052. - PMC - PubMed
    1. Rocca A, Bravaccini S, Scarpi E, Mangia A, Petroni S, Puccetti M, Medri L, Serra L, Ricci M, Cerasoli S, Biglia N, Maltoni R, Giunchi DC, Gianni L, Tienghi A, Brandi M, Faedi M, Sismondi P, Paradiso A, Silvestrini R, Amadori D. Benefit from anthracyclines in relation to biological profiles in early breast cancer. Breast Cancer Res Treat. 2014;144(2):307–318. - PubMed
    1. Anghel RM, Trifanescu OG, Mitrica RI, Curea FG, Botnariuc I, Herghelegiu CG, Orlov CM, Ilie SM. Good Prognosis Went Badly: Fulminant Evolution of a 29-Year-Old Patient with Verrucous Carcinoma of the Cervix. J Adolesc Young Adult Oncol. 2017 doi: 10.1089/jayao.2017.0009. - DOI - PubMed
    1. Scandinavian Breast Group Trial 9401. Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol. 2006;24(16):2428–2436. - PubMed
    1. Di Gioia D, Heinemann V, Nagel D, Untch M, Kahlert S, Bauerfeind I, Koehnke T, Stieber P. Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC) Tumour Biol. 2011;32(4):777–785. - PubMed

LinkOut - more resources